Last reviewed · How we verify
Thalidomide Pill
At a glance
| Generic name | Thalidomide Pill |
|---|---|
| Sponsor | Qilu Hospital of Shandong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Prevention of Treatment Induced Neuropathy in Multiple Myeloma (PHASE2)
- The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients (PHASE4)
- Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer (PHASE1, PHASE2)
- UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (PHASE2)
- Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer (PHASE3)
- The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients (PHASE3)
- Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thalidomide Pill CI brief — competitive landscape report
- Thalidomide Pill updates RSS · CI watch RSS
- Qilu Hospital of Shandong University portfolio CI